BRCA1 and neoplasm: BRCA1-mutated TNBC exhibits a unique tumor immune microenvironment characterized by higher mutational loads and extensive immune lymphocyte infiltration, suggesting that BRCA1 mutations could serve as potential biomarkers for ICI responses.